Save Money On Your Rx
- Researchers gain insights into the genetic and molecular machinery that predisposes individuals to Alzheimer's diseaseon August 5, 2022 at 7:43 pm
Researchers have achieved an unprecedented understanding of the genetic and molecular machinery in human microglia -- immune cells that reside in the brain -- that could provide valuable insights into how they contribute to the development and progression of Alzheimer's disease (AD).
- How microglia contribute to Alzheimer's diseaseon August 4, 2022 at 5:06 pm
A new study shows how a type of cells called microglia contribute to the slowdown of neuron activity seen in Alzheimer's disease. The study found that microglia that express the APOE4 gene, one of the strongest genetic risk factors for Alzheimer's disease, cannot metabolize lipids normally, leading to a buildup of excess lipids that interferes with nearby neurons' ability to communicate with each other.
- A new therapeutic drug for Alzheimer's disease without inflammatory side effectson August 4, 2022 at 5:05 pm
Although Aduhelm, a monoclonal antibody targeting amyloid beta (A?), recently became the first US FDA approved drug for Alzheimer's disease (AD) based on its ability to decrease A? plaque burden in AD patients, its effect on cognitive improvement is still controversial. Moreover, about 40% of the patients treated with this antibody experienced serious side effects including cerebral edemas (ARIA-E) and hemorrhages (ARIA-H) that are likely related to inflammatory responses in the brain when the A? antibody binds Fc receptors (FCR) of immune cells such as microglia and macrophages. Now there is a new option.
- A new therapeutic drug for Alzheimer's disease without inflammatory side effectson August 4, 2022 at 5:05 pm
Although Aduhelm, a monoclonal antibody targeting amyloid beta (A?), recently became the first US FDA approved drug for Alzheimer's disease (AD) based on its ability to decrease A? plaque burden in AD patients, its effect on cognitive improvement is still controversial. Moreover, about 40% of the patients treated with this antibody experienced serious side effects including cerebral edemas (ARIA-E) and hemorrhages (ARIA-H) that are likely related to inflammatory responses in the brain when the A? antibody binds Fc receptors (FCR) of immune cells such as microglia and macrophages. Now there is a new option.
- Education, job, and social life may help protect brain from cognitive declineon August 3, 2022 at 8:10 pm
Why do some people with amyloid plaques in their brains associated with Alzheimer's disease show no signs of the disease, while others with the same amount of plaque have clear memory and thinking problems? Researchers looked at genetic and life course factors that may help create a 'cognitive reserve' that provides a buffer against the disease.